Form 4: Axsome Therapeutics CCO Receives Performance Stock Units

Axsome Therapeutics Chief Commercial Officer Ari Maizel was granted 7,224 performance stock units tied to commercial milestones.

Summary

• Ari Maizel, Chief Commercial Officer of Axsome Therapeutics, was awarded 7,224 performance stock units (PSUs) on April 21, 2026.
• Each PSU represents a contingent right to receive one share of common stock.
• Vesting of these units is contingent upon the achievement of specific sales and commercial launch milestones.
• The reporting person must maintain continued service with the company to satisfy vesting requirements.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation practices rather than a material change in company outlook.

Positives

• Alignment of executive compensation with long-term commercial success and sales performance.
• Incentivizes the Chief Commercial Officer to drive growth and successful product launches.

Negatives

• Potential for future dilution of existing shareholders upon the vesting and conversion of these units into common stock.

Risks

• Failure to achieve the specified sales and commercial launch milestones would result in the forfeiture of these units.
• Dependence on the continued service of the executive to realize the value of the equity grant.

Future Outlook

The grant indicates management's focus on achieving specific commercial and sales milestones, suggesting an internal expectation of growth and product market penetration.

Management Comments

• Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

Industry Context

StockSavvy.ai notes that performance-based equity grants are standard practice in the biopharmaceutical industry to align executive incentives with the successful commercialization of drug pipelines.

Comparison to Industry Standards

• The use of performance-based vesting criteria is consistent with compensation structures at peer biotech firms like Biohaven or Intra-Cellular Therapies.
• Granting equity tied to commercial milestones is a common mechanism to mitigate risk for shareholders during the high-stakes product launch phase.

Stakeholder Impact

• Shareholders may experience minor dilution if milestones are met and shares are issued.
• Employees and management are incentivized toward achieving commercial targets.

Next Steps

• Monitoring of future commercial milestones to determine if vesting conditions are met.
• Tracking of potential share issuance upon the vesting of these units.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Insider Trading, Form 4, Executive Compensation, Performance Stock Units